<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01381016</url>
  </required_header>
  <id_info>
    <org_study_id>11-0293</org_study_id>
    <nct_id>NCT01381016</nct_id>
  </id_info>
  <brief_title>Estrogen Sensitivity and Ovulatory Dysfunction in Obesity</brief_title>
  <official_title>Estrogen Sensitivity and Ovulatory Dysfunction in Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The sole purpose of this study is to evaluate pathophysiology of disease. The disease state
      that is being evaluated is the obesity-related alterations in reproductive hormones

        -  The obesity epidemic in the United States is advancing at an accelerated pace. It is
           estimated that by 2015, 41% of U.S. adults will be obese as defined by a body mass index
           (BMI) of greater than 30 kg/m2. The U.S. government's 2010 Dietary Guidelines regard
           obesity as the single greatest health hazard in this century. Female adult obesity is
           associated with menstrual cycle irregularities, ovulatory dysfunction and a higher risk
           of obstetrical complications. This reproductive phenotype of obesity is worsened by
           further increases in BMI and is not solely due to anovulatory infertility. While the
           association of adiposity with subfertility is well documented in population studies, the
           underlying mechanisms remain poorly understood. The main objective of this proposal is
           to clarify the nature of the obesity-related reproductive endocrine abnormalities and
           identify potential etiologies amenable to therapy.

        -  Hypothesis: The hypothalamic-pituitary axis is abnormally sensitive to estradiol
           negative feedback in obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Design: paired assessments Pre and Post estrogen administration in obese and normal
           weight women

        -  AIM 1: To test the pituitary and hypothalamic responsiveness in obesity, we will examine
           the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) pulsatility during
           frequent blood sampling.

        -  AIM 2: To test the ovarian responsiveness in obesity, we will examine urinary
           reproductive hormones (E1c, estrone conjugates, and Pdg, pregnanediol glucuronide) over
           an entire menstrual cycle.

        -  AIM 3: To test the hypothesis that central adiposity is associated with reproductive
           hormone alterations in obesity, we will quantitatively assess body composition by dual
           energy x-ray absorptiometry (DXA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Luteinizing Hormone Pulse Amplitude</measure>
    <time_frame>Baseline</time_frame>
    <description>The study is powered on luteinizing hormone pulse amplitude because it is the clinical outcome for which the most data is available. The primary comparison is whether there is a significant reduction in the pulse amplitude in the obese between the pre- and post-treatment periods and whether there is no change in the pulse amplitude in the normal weight patients between the pre and post-treatment periods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Luteinizing Hormone Pulse Amplitude</measure>
    <time_frame>Post estradiol at one month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Obesity</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Group 1 - Normal Weight</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group 1: Normal weight (BMI 18-25 kg/m2)
Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Obese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: Obese (BMI &gt;30 kg/m2)
Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.</description>
    <arm_group_label>Group 1 - Normal Weight</arm_group_label>
    <arm_group_label>Group 2 - Obese</arm_group_label>
    <other_name>Climara, transdermal estrogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropin-releasing hormone (GnRH)</intervention_name>
    <description>Pituitary response was assessed to determine how estradiol administration alters pituitary sensitivity to GnRH.</description>
    <arm_group_label>Group 1 - Normal Weight</arm_group_label>
    <arm_group_label>Group 2 - Obese</arm_group_label>
    <other_name>Lutrelef or gonadorelin acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.</description>
    <arm_group_label>Group 1 - Normal Weight</arm_group_label>
    <arm_group_label>Group 2 - Obese</arm_group_label>
    <other_name>Prometrium or medroxyproge sterone acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-42 at study entry

          -  Regular menstrual cycles every 25-40 days

          -  BMI 18- 25 kg/m2 or â‰¥30kg/m2

          -  Good general health

          -  Prolactin and thyroid-stimulating hormone (TSH) within normal laboratory ranges at
             screening

          -  Baseline hemoglobin &gt;11 gm/dl.

        Exclusion Criteria:

          -  Positive screen for Activated Protein C resistance

          -  Any contraindications to exogenous estrogen, including previous thromboembolic events
             or stroke, history of an estrogen-dependent tumor, active liver disease, undiagnosed
             abnormal uterine bleeding, hypertriglyceridemia, smoking, hypertension

          -  History of chronic disease affecting hormone production, metabolism or clearance
             (including diabetes mellitus) or abnormal renal or liver function at screening, such
             as elevated aspartate or alanine aminotransferases or elevated blood urea nitrogen
             (BUN) or creatinine

          -  Current use of thiazolidinediones or metformin (known to interact with reproductive
             hormones)

          -  Use of hormones affecting hypothalamic-pituitary ovarian axis within three months of
             enrollment

          -  Strenuous exercise (&gt;4 hours per week)

          -  Pregnancy, breast-feeding or current active attempts to conceive
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Polotsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado, Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cudoctors.com/find-a-doctor/profile/?providerID=4029&amp;name=polotsky</url>
    <description>PI Profile</description>
  </link>
  <reference>
    <citation>Jain A, Polotsky AJ, Rochester D, Berga SL, Loucks T, Zeitlian G, Gibbs K, Polotsky HN, Feng S, Isaac B, Santoro N. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab. 2007 Jul;92(7):2468-73. Epub 2007 Apr 17.</citation>
    <PMID>17440019</PMID>
  </reference>
  <reference>
    <citation>Rochester D, Jain A, Polotsky AJ, Polotsky H, Gibbs K, Isaac B, Zeitlian G, Hickmon C, Feng S, Santoro N. Partial recovery of luteal function after bariatric surgery in obese women. Fertil Steril. 2009 Oct;92(4):1410-5. doi: 10.1016/j.fertnstert.2008.08.025. Epub 2008 Sep 30.</citation>
    <PMID>18829008</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>February 2, 2015</results_first_submitted>
  <results_first_submitted_qc>February 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 18, 2015</results_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LH pulsatility</keyword>
  <keyword>Obesity</keyword>
  <keyword>Reproduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Group 1 &quot;Control&quot;: Normal weight (BMI 18-25 kg/m2)
Estradiol, Lutrelef or gonadorelin</description>
        </group>
        <group group_id="P2">
          <title>Experimental</title>
          <description>Group 2 &quot;Experimental&quot;: Obese (BMI &gt;30 kg/m2)
Estradiol, Lutrelef or gonadorelin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Group 1 &quot;Control&quot;: Normal weight (BMI 18-25 kg/m2)
Estradiol, Lutrelef or gonadorelin</description>
        </group>
        <group group_id="B2">
          <title>Experimental</title>
          <description>Group 2 &quot;Experimental&quot;: Obese (BMI &gt;30 kg/m2)
Estradiol, Lutrelef or gonadorelin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="23" upper_limit="41"/>
                    <measurement group_id="B2" value="31.76" lower_limit="19" upper_limit="39"/>
                    <measurement group_id="B3" value="30.57" lower_limit="19" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Luteinizing Hormone Pulse Amplitude</title>
        <description>The study is powered on luteinizing hormone pulse amplitude because it is the clinical outcome for which the most data is available. The primary comparison is whether there is a significant reduction in the pulse amplitude in the obese between the pre- and post-treatment periods and whether there is no change in the pulse amplitude in the normal weight patients between the pre and post-treatment periods.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Normal Weight</title>
            <description>Group 1: Normal weight (BMI 18-25 kg/m2)
Estradiol, Lutrelef or gonadorelin</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Obese</title>
            <description>Group 2: Obese (BMI &gt;30 kg/m2)
Estradiol, Lutrelef or gonadorelin</description>
          </group>
        </group_list>
        <measure>
          <title>Luteinizing Hormone Pulse Amplitude</title>
          <description>The study is powered on luteinizing hormone pulse amplitude because it is the clinical outcome for which the most data is available. The primary comparison is whether there is a significant reduction in the pulse amplitude in the obese between the pre- and post-treatment periods and whether there is no change in the pulse amplitude in the normal weight patients between the pre and post-treatment periods.</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread=".46"/>
                    <measurement group_id="O2" value="1.12" spread=".19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Luteinizing Hormone Pulse Amplitude</title>
        <time_frame>Post estradiol at one month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Group 1: Normal weight (BMI 18-25 kg/m2)
Estradiol, Lutrelef or gonadorelin</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>Group 2: Obese (BMI &gt;30 kg/m2)
Estradiol, Lutrelef or gonadorelin</description>
          </group>
        </group_list>
        <measure>
          <title>Luteinizing Hormone Pulse Amplitude</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread=".4"/>
                    <measurement group_id="O2" value="1.59" spread=".29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>2/13 subjects enrolled as controls were considered screen failures, thus only 11 subjects were considered participants &quot;at risk&quot; in the control group.
2/17 subjects enrolled in experimental group were considered screen failures, thus only 15 subjects were considered participants &quot;at risk&quot; in the experimental group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Group 1 &quot;Control&quot;: Normal weight (BMI 18-25 kg/m2)
Estradiol, Lutrelef or gonadorelin</description>
        </group>
        <group group_id="E2">
          <title>Experimental</title>
          <description>Group 2 &quot;Experimental&quot;: Obese (BMI &gt;30 kg/m2)
Estradiol, Lutrelef or gonadorelin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Professor</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>(303) 724-2037</phone>
      <email>alex.polotsky@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

